A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Vorinostat (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms SAHA-I
- 01 Aug 2017 Results of pharmacokinetic/pharmacodynamic analysis (n=10) published in the Cancer Chemotherapy and Pharmacology
- 28 Jun 2016 Results published in the European Journal of Cancer
- 28 Jul 2012 Planned end date calculated from estimated duration in European Clinical Trials Database record.